European Commission Approved Nirogacestat for Desmoid Tumors – Merck Healthcare
Merck Healthcare shared a post on LinkedIn:
“The wait is over for the desmoid tumor patient community in Europe.
Today, the European Commission approved nirogacestat for adults with progressing desmoid tumors who require systemic treatment.
This marks our second European Commission approval in one month for conditions where there were previously very limited treatment options in Europe.
Congratulations and deep appreciation to our team, who work tirelessly to bring solutions to patients in need.
Watch the video attached to the post.
Belén Garijo, Chair of the Executive Board and CEO of Merck, shared a post on LinkedIn by Merck, adding:
“Two EU approvals within one month!
A huge congrats to the SpringWorks Therapeutics team for delivering once again to serve European patients in need.
Let’s keep up the great momentum.”
More posts featuring Merck Group on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023